INS and Alzheimer disease: Metabolic disorders have recently been highlighted as a potential cause and target for AD, including insulin signalling dysfunction and brain glucose metabolic disturbances, the latter suggested as hallmarks of AD and underlie the proposition that AD should be regarded as type III diabetes, specifically affecting the brain.